Consun Pharmaceutical Group Limited provided consolidated earnings guidance for the six months ended June 30, 2015. For the period, the company expects that the group would record an increase of approximately 25% to 30% in profit attributable to equity shareholders of the company as compared with that for the six-month period ended 30 June 2014, which was mainly attributable to the continued growth in sales of the Group's kidney medicines and medical contrast medium during the period, and the continuous improvement in business operation and management efficiency and cost control measurements during the period.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.45 HKD | -1.68% | -1.53% | +35.22% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+35.22% | 692M | |
+16.93% | 42.79B | |
+22.20% | 22.81B | |
+15.37% | 15.04B | |
+18.51% | 14.49B | |
+51.63% | 12.65B | |
-11.45% | 6.74B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+14.55% | 5.47B |
- Stock Market
- Equities
- 1681 Stock
- News Consun Pharmaceutical Group Limited
- Consun Pharmaceutical Group Limited Provides Consolidated Earnings Guidance for the Six Months Ended June 30, 2015